← brief for 2026-08-26 · Slowing decline

Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.

Key takeaways

A new dye used in imaging tests was studied in 40 people with kidney disease, including those on dialysis — the study found how quickly the body removes it, which helps doctors choose safer doses.

Who did this work

Han Q (Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.) · Zhang R (Clinical Trial Center, Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Jinan, China.) · He Y (Phase I Clinical Trial Laboratory, Guizhou Medical University Affiliated Hospital, Guiyang, China.) · Yan R (Nephrology Department, Guizhou Medical University Affiliated Hospital, Guiyang, China.) · Shi L (Phase I Clinical Trial Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.) · Wu N (Phase I Clinical Trial Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.) · Yu L (Department of Pharmacy, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.) · Muhetaer G (Department of Nephrology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.) · Meng X (Phase I Clinical Trial Laboratory, The Second People's Hospital of Hefei, Hefei, China.) · Liu L (Department of Nephrology, The Second People's Hospital of Hefei, Hefei, China.) · Yin T (Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.) · Huang Y (Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.)

Source

Paper · Europe PMC, CKD · 2026-08-22
https://doi.org/10.1007/s40262-026-01688-4